A new, freely accessible artificial intelligence platform is aiming to accelerate drug discovery for some of the world’s most pressing global health challenges. Launched jointly by the Medicines for Malaria Venture (MMV) and deepmirror, Drug Design for Global Health (dd4gh) offers researchers working on malaria, tuberculosis, and other neglected tropical diseases a powerful new tool without the often-prohibitive costs associated with similar technologies.
The platform, funded in part by the Bill & Melinda Gates Foundation, combines predictive and generative AI to analyze large datasets and propose potential drug compounds for laboratory testing. It’s designed to lower the barrier to entry for researchers in resource-limited settings, where access to advanced computational tools is often restricted. This initiative arrives at a critical time, as global funding for research and development into neglected diseases remains significantly below peak levels.
“AI tools for drug discovery are known to researchers in resource-limited settings, but licensing costs can still put them out of reach,” says Caroline Maina, a PhD candidate at the University of Cape Town, in a statement on the dd4gh website. The platform directly addresses this issue by providing a no-cost option for qualified researchers.
Leveling the Playing Field in Global Health Research
dd4gh isn’t simply a software package; it’s built on a foundation of collaboration and curated data. MMV contributes its extensive datasets and medicinal chemistry expertise in malaria and neglected tropical disease drug discovery, while deepmirror provides the underlying AI and machine learning infrastructure. The platform utilizes active learning, meaning it improves its predictive capabilities as it’s exposed to new experimental data.
Researchers can also leverage pre-trained models built on MMV’s curated datasets, allowing them to jumpstart their projects even before generating their own data. This feature is particularly valuable for those starting new research programs or lacking extensive in-house datasets. The platform prioritizes data privacy, ensuring that uploaded information remains confidential and is not shared with other users.
The development of dd4gh wasn’t conducted in a vacuum. In September 2025, deepmirror hosted a workshop in Geneva, bringing together over 40 scientists to refine the platform’s functionality. This was followed by a second workshop planned for Accra, specifically focused on researchers based in Africa working on malaria, tuberculosis, and neglected tropical diseases, according to a deepmirror blog post.
A Growing Funding Gap for Neglected Diseases
The launch of dd4gh comes as investment in research and development for neglected tropical diseases faces ongoing challenges. According to the World Health Organization’s (WHO) neglected-disease R&D dashboard, based on G-FINDER data, total investment in 2022 reached approximately $3.93 billion. However, funding remains heavily concentrated in research for HIV/AIDS, tuberculosis, and malaria, accounting for over 70% of the total.
The G-FINDER 2024 report further illustrates this trend, noting that global funding for basic research and product development for neglected diseases reached $4.17 billion in 2023 – nearly $650 million less than in 2018, as detailed in the report summary. The WHO highlights that these diseases are often characterized by “market failure,” meaning the commercial incentive for private investment is insufficient to drive the necessary research and development.
This lack of commercial viability is precisely what dd4gh aims to address. By providing a free, accessible platform, the initiative hopes to empower researchers to overcome financial barriers and accelerate the development of new treatments and preventative measures.
Access and Eligibility
Access to dd4gh is granted to individual researchers, not institutions, and applicants must demonstrate involvement in compound design and a focus on diseases relevant to global health. All research conducted using the platform must be non-commercial in nature. Approved users can opt for a virtual onboarding session with the deepmirror team to familiarize themselves with the platform’s features and capabilities. Researchers interested in applying can do so directly through the dd4gh website.
The platform represents a significant step towards democratizing drug discovery, offering a powerful tool to those working on the front lines of global health. As dd4gh matures and more researchers start utilizing its capabilities, it has the potential to significantly impact the fight against malaria, tuberculosis, and other neglected tropical diseases.
The team plans to continue refining the platform based on user feedback and expanding its capabilities. The next major milestone will be a comprehensive evaluation of the platform’s impact on research productivity, scheduled for the fourth quarter of 2026.
Please note: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Share your thoughts on this new platform and its potential impact in the comments below.
